# US 2003/0077798 A1 · GSK3 polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077798 A1
- Document ID: US20030077798A1
- Status: Published application
- Kind: A1
- Application number: 10/211,412
- Filed: 2002-07-31
- Published: 2003-04-24
- Earliest claimed: 2000-07-27
- Assignees: Chiron Corporation
- Inventors: Stephen D. Harrison; John A. Hall; Maria Calderon-Cacia; Ziyang Zhong; Eric Y. Fang; Doris G. Coit; Steve H. Nguyen; Angelica Medina-Selby
- Web page: https://patentgrep.com/patent/US20030077798A1

## CPC

- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/485: {involving kinase}
- C12Y 207/01037: Protein kinase (2.7.1.37) (C12Y207/11001, C12Y207/11008 - C12Y207/11013, C12Y207/11021, C12Y207/11022, C12Y207/11024, C12Y207/11025, C12Y207/1103, C12Y207/12001 take precedence)
- G01N 2500/00: Screening for compounds of potential therapeutic value
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

## Claims

### Claim 1

An isolated nucleic acid comprising a polynucleotide encoding a polypeptide consisting essentially of SEQ ID NO:2, wherein said polypeptide will crystallize and will have at least one biological activity selected from the group consisting of (a) binding a GSK3 inhibitor; and (b) kinase activity.

### Claim 2

An isolated nucleic acid comprising a polynucleotide encoding a polypeptide consisting essentially of SEQ ID NO:3, wherein said polypeptide will crystallize and will have at least one biological activity selected from the group consisting of (a) binding a GSK3 inhibitor; and (b) kinase activity.

### Claim 3 (depends on 1, 2)

A vector comprising the polynucleotide of claim 1 or claim 2.

### Claim 4

A polypeptide comprising between about 250 and 419 contiguous amino acids of SEQ ID NO:1, wherein said polypeptide is phosphorylated on tyrosine 216, said polypeptide will crystallize, and said polypeptide will have at least one biological activity selected from the group consisting of (a) binding a GSK3 inhibitor; and (b) kinase activity.

### Claim 5

A polypeptide consisting essentially of between about 278 and 419 contiguous amino acids of SEQ ID NO:1, wherein said polypeptide exhibits at least 1% of the kinase activity of human GSK3β.

### Claim 6

A polypeptide consisting essentially of between about 285 and 384 contiguous amino acids of SEQ ID NO:1, wherein said polypeptide exhibits at least 1% of the kinase activity of human GSK3β.

### Claim 7

A polypeptide consisting essentially of between about 351 and 384 contiguous amino acids of SEQ ID NO:1, wherein said polypeptide exhibits at least 1% of the kinase activity of human GSK3β.

### Claim 8

A polypeptide consisting of the amino acid sequence of SEQ ID NO:2.

### Claim 9

A polypeptide consisting of the amino acid sequence of SEQ ID NO:3.

### Claim 10

An isolated nucleic acid comprising a polynucleotide encoding a polypeptide consisting essentially of SEQ ID NO:5, wherein said polypeptide will crystallize and will have at least one biological activity selected from the group consisting of (a) binding to a GSK3 inhibitor; and (b) kinase activity.

### Claim 11 (depends on 10)

The nucleic acid of claim 10 wherein said polypeptide is phosphorylated on tyrosine 279.

### Claim 12 (depends on 10, 11)

A vector comprising the polynucleotide of claim 10 or claim 11.

### Claim 13

A polypeptide comprising between about 182 and 482 contiguous amino acids of SEQ ID NO:4, wherein said polypeptide will crystallize, and said polypeptide will have at least one biological activity selected from the group consisting of (a) binding a GSK3 inhibitor; and (b) kinase activity.

### Claim 14

A polypeptide consisting essentially of between about 182 and 386 contiguous amino acids of SEQ ID NO:4, wherein said polypeptide exhibits at least 1% of the kinase activity of human GSK3α.

### Claim 15

A polypeptide consisting essentially of between about 182 and 351 contiguous amino acids of SEQ ID NO:4, wherein said polypeptide exhibits at least 1% of the kinase activity of human GSK3α.

### Claim 16

A polypeptide consisting essentially of contiguous amino acids S97 to S447 of SEQ ID NO: 1.

### Claim 17

A polypeptide consisting essentially of the amino acid sequence of SEQ ID NO:5.

### Claim 18

A polynucleotide encoding a polypeptide consisting essentially of SEQ ID NO:6.

### Claim 19

A polypeptide consisting essentially of the amino acid sequence of SEQ ID NO:6.

### Claim 20

A polynucleotide encoding a polypeptide consisting essentially of SEQ ID NO:7.

### Claim 21

A polypeptide consisting essentially of the amino acid sequence of SEQ ID NO:7.

### Claim 22

A polynucleotide encoding a non-phosphorylated human GSK3 polypeptide, wherein said non-phosphorylated polypeptide differs from native GSK3 in at least one and not more than ten amino acids.

### Claim 23 (depends on 22)

The polynucleotide of claim 22 wherein tyrosine at position 216 of SEQ ID NO:1 is substituted for by a non-phosphorylatable amino acid.

### Claim 24 (depends on 23)

The polynucleotide of claim 23 wherein said non-phosphorylatable amino acid is phenylalanine.

### Claim 25 (depends on 22)

The polynucleotide of claim 22 wherein tyrosine at position 279 of SEQ ID NO:4 is substituted for by a non-phosphorylatable amino acid.

### Claim 26 (depends on 25)

The polynucleotide of claim 25 wherein said non-phosphorylatable amino acid is phenylalanine.
